Cabenuva is a long-acting injectable antiretroviral therapy used in the management of human immunodeficiency virus type 1 (HIV-1) infection. It represents a shift from traditional daily oral regimens toward extended-interval intramuscular treatment. The therapy combines two active agents—cabotegravir and rilpivirine—administered together as separate injections during the same visit. This formulation is designed for individuals with virologically suppressed HIV-1 infection who meet specific clinical criteria. This article provides an in-depth review of dosing structure, approved uses, clinical considerations, and cost factors associated with Cabenuva. The discussion is informational in nature and does not constitute medical advice or product promotion.
Background and Mechanism of Action
Cabenuva contains two antiretroviral agents with complementary mechanisms:
Cabotegravir, an integrase strand transfer inhibitor (INSTI), blocks the integration of viral DNA into the host genome.
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), interferes with viral replication by binding to reverse transcriptase.
By combining these agents, Cabenuva suppresses viral replication in individuals whose HIV infection is already controlled on a stable oral regimen. The injectable format allows sustained drug levels in the body over several weeks.
Long-acting antiretroviral strategies were developed to address adherence challenges associated with daily oral therapy. Maintaining consistent viral suppression reduces the risk of disease progression and transmission.
Approved Uses
Cabenuva is approved for the treatment of HIV-1 infection in adults and certain adolescents who meet defined criteria. Indications generally include:
Virologically suppressed HIV-1 infection on a stable antiretroviral regimen
No history of treatment failure
No known or suspected resistance to cabotegravir or rilpivirine
The therapy is not indicated for the initiation of treatment in individuals with uncontrolled viral replication. Instead, it serves as a maintenance strategy following successful suppression achieved with oral therapy.
Clinical eligibility assessment typically involves review of viral load history, resistance testing records, and overall treatment stability.
Dosing Structure
Cabenuva is administered via intramuscular injection into the gluteal muscle. Two injections are given during each dosing visit—one containing cabotegravir and the other containing rilpivirine.
Initiation Phase
Some treatment protocols begin with an oral lead-in period using oral cabotegravir and rilpivirine. This step allows assessment of tolerability before long-acting injections are introduced. In certain updated prescribing frameworks, direct-to-injection initiation without oral lead-in may also be considered, depending on clinical evaluation and regulatory guidance.
Loading Doses
The initial injectable phase includes higher loading doses administered one month apart. These doses establish therapeutic drug levels in the body.
Maintenance Dosing
After the loading phase, maintenance injections are typically scheduled either:
Every month (approximately every four weeks), or
Every two months (approximately every eight weeks), depending on the selected regimen and regulatory approval in the relevant jurisdiction.
Adherence to the dosing schedule is essential to maintain consistent drug concentrations. Missed doses may require bridging therapy or re-initiation protocols to prevent viral rebound.
Administration Considerations
Injections are administered by trained healthcare professionals in a clinical setting. Proper injection technique is important to reduce discomfort and ensure correct drug absorption.
Injection site reactions are among the most frequently reported adverse events. These reactions may include:
Pain
Swelling
Redness
Nodules at the injection site
Most reactions are mild to moderate and resolve without intervention. Systemic side effects may include fever, fatigue, headache, or gastrointestinal symptoms, though these are generally less common.
Monitoring includes periodic viral load testing to confirm continued suppression. Laboratory evaluation schedules vary according to clinical standards and regional treatment guidelines.
Clinical Trial Evidence
The approval of Cabenuva was supported by multiple phase III clinical trials comparing long-acting injectable therapy to continued daily oral antiretroviral regimens. These trials demonstrated non-inferiority in maintaining viral suppression among eligible participants.
Participants receiving injectable therapy reported high treatment satisfaction scores in certain study populations. However, individual experience varies, and injectable therapy may not suit all patients.
Long-term extension studies continue to evaluate durability, resistance patterns, and safety over extended periods.
Special Populations and Precautions
Certain populations require additional clinical consideration:
Individuals with hepatitis B coinfection may need alternative or supplemental therapy, as Cabenuva does not provide activity against hepatitis B virus.
Pregnancy and breastfeeding considerations require individualized risk assessment.
Drug interactions must be reviewed carefully, particularly with medications that induce liver enzymes affecting rilpivirine levels.